SSX2 and synovial sarcoma: Parker and colleagues supported the role of FYN proto‐oncogene, Src family tyrosine kinase (FYN) in suppressing anti‐cancer activity through SS18‐SSX functional inhibition in order to improve the effectiveness of genetic and histone deacetylase inhibitor (HDACi) treatment against synovial sarcoma [185].